{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:46:44Z","timestamp":1787496404725,"version":"build-2736575974"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00125-023-05966-9","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T03:02:31Z","timestamp":1690426951000},"page":"1846-1858","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease"],"prefix":"10.1007","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9863-2644","authenticated-orcid":false,"given":"Christine R.","family":"Andreasen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8190-5140","authenticated-orcid":false,"given":"Andreas","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0456-6787","authenticated-orcid":false,"given":"Tina","family":"Vilsb\u00f8ll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"issue":"7","key":"5966_CR1","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/OBR.1255110.1111\/obr.12551","volume":"18","author":"GA Bray","year":"2017","unstructured":"Bray GA, Kim KK, Wilding JPH (2017) Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev 18(7):715\u2013723. https:\/\/doi.org\/10.1111\/OBR.1255110.1111\/obr.12551","journal-title":"Obes Rev"},{"issue":"9945","key":"5966_CR2","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0140-6736(14)60460-8","volume":"384","author":"M Ng","year":"2014","unstructured":"Ng M, Fleming T, Robinson M et al (2014) Global, regional, and national prevalence of overweight and obesity in children and adults during 1980\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 384(9945):766\u2013781. https:\/\/doi.org\/10.1016\/S0140-6736(14)60460-8","journal-title":"Lancet"},{"key":"5966_CR3","doi-asserted-by":"publisher","DOI":"10.1111\/DOM.14947","author":"A Potteg\u00e5rd","year":"2022","unstructured":"Potteg\u00e5rd A, Andersen JH, S\u00f8ndergaard J, Thomsen RW, Vilsb\u00f8ll T (2022) Changes in the use of glucose-lowering drugs: a Danish nationwide study. Diabetes Obes Metab. https:\/\/doi.org\/10.1111\/DOM.14947","journal-title":"Diabetes Obes Metab"},{"issue":"S3","key":"5966_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/DOM.14500","volume":"23","author":"CR Andreasen","year":"2021","unstructured":"Andreasen CR, Andersen A, Knop FK, Vilsb\u00f8ll T (2021) Understanding the place for GLP-1RA therapy: translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. Diabetes Obes Metab 23(S3):40\u201352. https:\/\/doi.org\/10.1111\/DOM.14500","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"5966_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/nejmoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385(6):503\u2013515. https:\/\/doi.org\/10.1056\/nejmoa2107519","journal-title":"N Engl J Med"},{"issue":"209","key":"5966_CR6","doi-asserted-by":"publisher","first-page":"209ra151","DOI":"10.1126\/SCITRANSLMED.3007218","volume":"5","author":"B Finan","year":"2013","unstructured":"Finan B, Ma T, Ottaway N et al (2013) Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med 5(209):209ra151. https:\/\/doi.org\/10.1126\/SCITRANSLMED.3007218","journal-title":"Sci Transl Med"},{"issue":"1","key":"5966_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/J.CMET.2016.06.021","volume":"24","author":"MH Tsch\u00f6p","year":"2016","unstructured":"Tsch\u00f6p MH, Finan B, Clemmensen C et al (2016) Unimolecular polypharmacy for treatment of diabetes and obesity. Cell Metab 24(1):51\u201362. https:\/\/doi.org\/10.1016\/J.CMET.2016.06.021","journal-title":"Cell Metab"},{"issue":"3","key":"5966_CR8","doi-asserted-by":"publisher","first-page":"e167952","DOI":"10.1172\/JCI167952","volume":"133","author":"J Bass","year":"2023","unstructured":"Bass J, Tsch\u00f6p MH, Beutler LR (2023) Dual gut hormone receptor agonists for diabetes and obesity. J Clin Invest 133(3):e167952. https:\/\/doi.org\/10.1172\/JCI167952","journal-title":"J Clin Invest"},{"issue":"4","key":"5966_CR9","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Golabi P, de Avila L et al (2019) The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 71(4):793\u2013801. https:\/\/doi.org\/10.1016\/j.jhep.2019.06.021","journal-title":"J Hepatol"},{"issue":"12","key":"5966_CR10","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1016\/j.cgh.2021.12.002","volume":"20","author":"MH Le","year":"2022","unstructured":"Le MH, Yeo YH, Li X et al (2022) 2019 global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 20(12):2809-2817.e28. https:\/\/doi.org\/10.1016\/j.cgh.2021.12.002","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"5966_CR11","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.2337\/DBI21-0026","volume":"70","author":"JJ Holst","year":"2021","unstructured":"Holst JJ (2021) Treatment of type 2 diabetes and obesity on the basis of the incretin system: the 2021 Banting Medal for Scientific Achievement award lecture. Diabetes 70(11):2468\u20132475. https:\/\/doi.org\/10.2337\/DBI21-0026","journal-title":"Diabetes"},{"issue":"4","key":"5966_CR12","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/J.CMET.2018.03.001","volume":"27","author":"DJ Drucker","year":"2018","unstructured":"Drucker DJ (2018) Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 27(4):740\u2013756. https:\/\/doi.org\/10.1016\/J.CMET.2018.03.001","journal-title":"Cell Metab"},{"issue":"6","key":"5966_CR13","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/J.CMET.2013.04.008","volume":"17","author":"JE Campbell","year":"2013","unstructured":"Campbell JE, Drucker DJ (2013) Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab 17(6):819\u2013837. https:\/\/doi.org\/10.1016\/J.CMET.2013.04.008","journal-title":"Cell Metab"},{"issue":"7","key":"5966_CR14","doi-asserted-by":"publisher","first-page":"R200","DOI":"10.1530\/ec-21-0130","volume":"10","author":"CR Andreasen","year":"2021","unstructured":"Andreasen CR, Andersen A, Knop FK, Vilsb\u00f8ll T (2021) How glucagon-like peptide 1 receptor agonists work. Endocr Connect 10(7):R200\u2013R212. https:\/\/doi.org\/10.1530\/ec-21-0130","journal-title":"Endocr Connect"},{"issue":"6560","key":"5966_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/379069a0","volume":"379","author":"MD Turton","year":"1996","unstructured":"Turton MD, O\u2019Shea D, Gunn I et al (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379(6560):69\u201372. https:\/\/doi.org\/10.1038\/379069a0","journal-title":"Nature"},{"key":"5966_CR16","doi-asserted-by":"publisher","first-page":"101351","DOI":"10.1016\/J.MOLMET.2021.101351","volume":"57","author":"DJ Drucker","year":"2022","unstructured":"Drucker DJ (2022) GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 57:101351. https:\/\/doi.org\/10.1016\/J.MOLMET.2021.101351","journal-title":"Mol Metab"},{"key":"5966_CR17","doi-asserted-by":"publisher","first-page":"106022","DOI":"10.1016\/J.APPET.2022.106022","volume":"174","author":"C Smith","year":"2022","unstructured":"Smith C, Patterson-Cross R, Woodward O et al (2022) A comparative transcriptomic analysis of glucagon-like peptide-1 receptor- and glucose-dependent insulinotropic polypeptide-expressing cells in the hypothalamus. Appetite 174:106022. https:\/\/doi.org\/10.1016\/J.APPET.2022.106022","journal-title":"Appetite"},{"issue":"7","key":"5966_CR18","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/NM727","volume":"8","author":"K Miyawaki","year":"2002","unstructured":"Miyawaki K, Yamada Y, Ban N et al (2002) Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 8(7):738\u2013742. https:\/\/doi.org\/10.1038\/NM727","journal-title":"Nat Med"},{"key":"5966_CR19","doi-asserted-by":"publisher","first-page":"101139","DOI":"10.1016\/J.MOLMET.2020.101139","volume":"46","author":"JE Campbell","year":"2021","unstructured":"Campbell JE (2021) Targeting the GIPR for obesity: to agonize or antagonize? Potential mechanisms. Mol Metab 46:101139. https:\/\/doi.org\/10.1016\/J.MOLMET.2020.101139","journal-title":"Mol Metab"},{"key":"5966_CR20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1210\/endrev\/bnaa032","volume":"42","author":"BA McLean","year":"2021","unstructured":"McLean BA, Wong CK, Campbell JE, Hodson DJ, Trapp S, Drucker DJ (2021) Revisiting the complexity of GLP-1 action from sites of synthesis to receptor activation. Endocr Rev 42:101\u2013132. https:\/\/doi.org\/10.1210\/endrev\/bnaa032","journal-title":"Endocr Rev"},{"issue":"11","key":"5966_CR21","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1016\/J.CELREP.2019.05.055","volume":"27","author":"EM Varin","year":"2019","unstructured":"Varin EM, Mulvihill EE, Baggio LL et al (2019) Distinct neural sites of GLP-1R expression mediate physiological versus pharmacological control of incretin action. Cell Rep 27(11):3371-3384.e3. https:\/\/doi.org\/10.1016\/J.CELREP.2019.05.055","journal-title":"Cell Rep"},{"issue":"6","key":"5966_CR22","doi-asserted-by":"publisher","first-page":"e133429","DOI":"10.1172\/jci.insight.133429","volume":"5","author":"S Gabery","year":"2020","unstructured":"Gabery S, Salinas CG, Paulsen SJ et al (2020) Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 5(6):e133429. https:\/\/doi.org\/10.1172\/jci.insight.133429","journal-title":"JCI Insight"},{"issue":"6","key":"5966_CR23","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1172\/JCI72434","volume":"124","author":"S Sisley","year":"2014","unstructured":"Sisley S, Gutierrez-Aguilar R, Scott M, D\u2019Alessio DA, Sandoval DA, Seeley RJ (2014) Neuronal GLP1R mediates liraglutide\u2019s anorectic but not glucose-lowering effect. J Clin Invest 124(6):2456\u20132463. https:\/\/doi.org\/10.1172\/JCI72434","journal-title":"J Clin Invest"},{"issue":"3","key":"5966_CR24","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/DOM.14280","volume":"23","author":"M Friedrichsen","year":"2021","unstructured":"Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D (2021) The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 23(3):754\u2013762. https:\/\/doi.org\/10.1111\/DOM.14280","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"5966_CR25","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/DOM.12506","volume":"17","author":"L van Bloemendaal","year":"2015","unstructured":"van Bloemendaal L, Veltman DJ, Ten Kulve JS et al (2015) Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans. Diabetes Obes Metab 17(9):878\u2013886. https:\/\/doi.org\/10.1111\/DOM.12506","journal-title":"Diabetes Obes Metab"},{"issue":"11","key":"5966_CR26","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMOA2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384(11):989\u20131002. https:\/\/doi.org\/10.1056\/NEJMOA2032183","journal-title":"N Engl J Med"},{"issue":"7","key":"5966_CR27","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41574-018-0016-2","volume":"14","author":"A Andersen","year":"2018","unstructured":"Andersen A, Lund A, Knop FK, Vilsb\u00f8ll T (2018) Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol 14(7):390\u2013403. https:\/\/doi.org\/10.1038\/s41574-018-0016-2","journal-title":"Nat Rev Endocrinol"},{"key":"5966_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff AM, Aronne LJ, Ahmad NN et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387:205\u2013216. https:\/\/doi.org\/10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"issue":"11","key":"5966_CR29","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1038\/IJO.2013.120","volume":"37","author":"TA Wadden","year":"2013","unstructured":"Wadden TA, Hollander P, Klein S et al (2013) Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study. Int J Obes 37(11):1443\u20131451. https:\/\/doi.org\/10.1038\/IJO.2013.120","journal-title":"Int J Obes"},{"issue":"1","key":"5966_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K et al (2015) A randomized, controlled trial of 30 mg of liraglutide in weight management. N Engl J Med 373(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892","journal-title":"N Engl J Med"},{"issue":"7","key":"5966_CR31","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B et al (2015) Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA 314(7):687\u2013699. https:\/\/doi.org\/10.1001\/jama.2015.9676","journal-title":"JAMA"},{"issue":"8","key":"5966_CR32","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/IJO.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G et al (2016) Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes 40(8):1310. https:\/\/doi.org\/10.1038\/IJO.2016.52","journal-title":"Int J Obes"},{"issue":"10077","key":"5966_CR33","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW Le Roux","year":"2017","unstructured":"Le Roux CW, Astrup AV, Fujioka K et al (2017) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet 389(10077):1399\u20131409. https:\/\/doi.org\/10.1016\/S0140-6736(17)30069-7","journal-title":"Lancet"},{"issue":"2","key":"5966_CR34","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/JAMA.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U et al (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 327(2):138\u2013150. https:\/\/doi.org\/10.1001\/JAMA.2021.23619","journal-title":"JAMA"},{"issue":"10278","key":"5966_CR35","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","volume":"397","author":"M Davies","year":"2021","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK et al (2021) Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 397(10278):971\u2013984. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-0","journal-title":"Lancet"},{"issue":"14","key":"5966_CR36","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/JAMA.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK et al (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 325(14):1403\u20131413. https:\/\/doi.org\/10.1001\/JAMA.2021.1831","journal-title":"JAMA"},{"issue":"14","key":"5966_CR37","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/JAMA.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M et al (2021) Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325(14):1414\u20131425. https:\/\/doi.org\/10.1001\/JAMA.2021.3224","journal-title":"JAMA"},{"issue":"10","key":"5966_CR38","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/S41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M et al (2022) Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28(10):2083\u20132091. https:\/\/doi.org\/10.1038\/S41591-022-02026-4","journal-title":"Nat Med"},{"issue":"3","key":"5966_CR39","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S2213-8587(22)00008-0","volume":"10","author":"T Kadowaki","year":"2022","unstructured":"Kadowaki T, Isendahl J, Khalid U et al (2022) Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol 10(3):193\u2013206. https:\/\/doi.org\/10.1016\/S2213-8587(22)00008-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"24","key":"5966_CR40","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMOA2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber D, Barrett T, Barrientos-P\u00e9rez M et al (2022) Once-weekly semaglutide in adolescents with obesity. N Engl J Med 387(24):2245\u20132257. https:\/\/doi.org\/10.1056\/NEJMOA2208601","journal-title":"N Engl J Med"},{"issue":"1","key":"5966_CR41","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/DOM.14863","volume":"25","author":"NC Bergmann","year":"2023","unstructured":"Bergmann NC, Davies MJ, Lingvay I, Knop FK (2023) Semaglutide for the treatment of overweight and obesity: a review. Diabetes Obes Metab 25(1):18\u201335. https:\/\/doi.org\/10.1111\/DOM.14863","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"5966_CR42","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1080\/17512433.2022.2130760","volume":"15","author":"Q Lin","year":"2022","unstructured":"Lin Q, Xue Y, Zou H, Ruan Z, Ung COL, Hu H (2022) Efficacy and safety of liraglutide for obesity and people who are overweight: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol 15(12):1461\u20131469. https:\/\/doi.org\/10.1080\/17512433.2022.2130760","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"10295","key":"5966_CR43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP et al (2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398(10295):143\u2013155. https:\/\/doi.org\/10.1016\/S0140-6736(21)01324-6","journal-title":"Lancet"},{"issue":"10300","key":"5966_CR44","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(21)01443-4","volume":"398","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E et al (2021) Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 398(10300):583\u2013598. https:\/\/doi.org\/10.1016\/S0140-6736(21)01443-4","journal-title":"Lancet"},{"issue":"10313","key":"5966_CR45","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/S0140-6736(21)02188-7","volume":"398","author":"S Del Prato","year":"2021","unstructured":"Del Prato S, Kahn SE, Pavo I et al (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398(10313):1811\u20131824. https:\/\/doi.org\/10.1016\/S0140-6736(21)02188-7","journal-title":"Lancet"},{"issue":"6","key":"5966_CR46","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1001\/jama.2022.0078","volume":"327","author":"D Dahl","year":"2022","unstructured":"Dahl D, Onishi Y, Norwood P et al (2022) Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA 327(6):534\u2013545. https:\/\/doi.org\/10.1001\/jama.2022.0078","journal-title":"JAMA"},{"key":"5966_CR47","unstructured":"Lilly (2023) Lilly\u2019s tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2. Available from: https:\/\/investor.lilly.com\/node\/48776\/pdf. Accessed: 4 May 2023"},{"key":"5966_CR48","unstructured":"Amgen (2022) Amgen presents new AMG 133 Phase 1 clinical data at WCIRDC 2022. Available from: www.amgen.com\/newsroom\/press-releases\/2022\/12\/amgen-presents-new-amg-133-phase-1-clinical-data-at-wcirdc-2022. Accessed: 2 March 2023"},{"issue":"11","key":"5966_CR49","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.2337\/DB14-0242","volume":"63","author":"J Cegla","year":"2014","unstructured":"Cegla J, Troke RC, Jones B et al (2014) Coinfusion of low-dose GLP-1 and glucagon in man results in a reduction in food intake. Diabetes 63(11):3711\u20133720. https:\/\/doi.org\/10.2337\/DB14-0242","journal-title":"Diabetes"},{"key":"5966_CR50","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/J.MOLMET.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR et al (2019) Glucagon-like peptide 1 (GLP-1). Mol Metab 30:72\u2013130. https:\/\/doi.org\/10.1016\/J.MOLMET.2019.09.010","journal-title":"Mol Metab"},{"issue":"10366","key":"5966_CR51","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","volume":"400","author":"S Urva","year":"2022","unstructured":"Urva S, Coskun T, Loh MT et al (2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet 400(10366):1869\u20131881. https:\/\/doi.org\/10.1016\/S0140-6736(22)02033-5","journal-title":"Lancet"},{"issue":"10317","key":"5966_CR52","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","volume":"398","author":"DCW Lau","year":"2021","unstructured":"Lau DCW, Erichsen L, Francisco AM et al (2021) Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet 398(10317):2160\u20132172. https:\/\/doi.org\/10.1016\/S0140-6736(21)01751-7","journal-title":"Lancet"},{"issue":"10286","key":"5966_CR53","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","volume":"397","author":"LB Enebo","year":"2021","unstructured":"Enebo LB, Berthelsen KK, Kankam M et al (2021) Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet 397(10286):1736\u20131748. https:\/\/doi.org\/10.1016\/S0140-6736(21)00845-X","journal-title":"Lancet"},{"issue":"1","key":"5966_CR54","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clinthera.2007.01.015","volume":"29","author":"JB Buse","year":"2007","unstructured":"Buse JB, Klonoff DC, Nielsen LL et al (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 29(1):139\u2013153. https:\/\/doi.org\/10.1016\/j.clinthera.2007.01.015","journal-title":"Clin Ther"},{"issue":"7","key":"5966_CR55","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/J.GASTRO.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J et al (2020) MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 158(7):1999-2014.e1. https:\/\/doi.org\/10.1053\/J.GASTRO.2019.11.312","journal-title":"Gastroenterology"},{"issue":"5","key":"5966_CR56","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/HEP.31173","volume":"72","author":"JM Paik","year":"2020","unstructured":"Paik JM, Golabi P, Younossi Y, Mishra A, Younossi ZM (2020) Changes in the global burden of chronic liver diseases from 2012 to 2017: the growing impact of NAFLD. Hepatology 72(5):1605\u20131616. https:\/\/doi.org\/10.1002\/HEP.31173","journal-title":"Hepatology"},{"issue":"12","key":"5966_CR57","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/JAMA.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S (2020) Nonalcoholic steatohepatitis: a review. JAMA 323(12):1175\u20131183. https:\/\/doi.org\/10.1001\/JAMA.2020.2298","journal-title":"JAMA"},{"issue":"1","key":"5966_CR58","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/J.JHEP.2014.12.012","volume":"62","author":"CD Byrne","year":"2015","unstructured":"Byrne CD, Targher G (2015) NAFLD: a multisystem disease. J Hepatol 62(1):S47\u2013S64. https:\/\/doi.org\/10.1016\/J.JHEP.2014.12.012","journal-title":"J Hepatol"},{"issue":"1","key":"5966_CR59","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/J.CMET.2019.12.002","volume":"31","author":"S Romeo","year":"2020","unstructured":"Romeo S, Sanyal A, Valenti L (2020) Leveraging human genetics to identify potential new treatments for fatty liver disease. Cell Metab 31(1):35\u201345. https:\/\/doi.org\/10.1016\/J.CMET.2019.12.002","journal-title":"Cell Metab"},{"issue":"1","key":"5966_CR60","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/IJO.2009.216","volume":"34","author":"S Romeo","year":"2010","unstructured":"Romeo S, Sentinelli F, Dash S et al (2010) Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes 34(1):190\u2013194. https:\/\/doi.org\/10.1038\/IJO.2009.216","journal-title":"Int J Obes"},{"issue":"7","key":"5966_CR61","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","volume":"6","author":"G Targher","year":"2021","unstructured":"Targher G, Tilg H, Byrne CD (2021) Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. Lancet Gastroenterol Hepatol 6(7):578\u2013588. https:\/\/doi.org\/10.1016\/S2468-1253(21)00020-0","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"5966_CR62","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","volume":"7","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Byrne CD, Targher G (2022) Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. Lancet Gastroenterol Hepatol 7(4):367\u2013378. https:\/\/doi.org\/10.1016\/S2468-1253(21)00261-2","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"5966_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nm.3761","volume":"21","author":"B Finan","year":"2014","unstructured":"Finan B, Yang B, Ottaway N et al (2014) A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med 21(1):27\u201336. https:\/\/doi.org\/10.1038\/nm.3761","journal-title":"Nat Med"},{"issue":"5","key":"5966_CR64","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.molmet.2017.02.002","volume":"6","author":"S Jall","year":"2017","unstructured":"Jall S, Sachs S, Clemmensen C et al (2017) Monomeric GLP-1\/GIP\/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice. Mol Metab 6(5):440\u2013446. https:\/\/doi.org\/10.1016\/j.molmet.2017.02.002","journal-title":"Mol Metab"},{"issue":"10","key":"5966_CR65","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/NCHEMBIO.209","volume":"5","author":"JW Day","year":"2009","unstructured":"Day JW, Ottaway N, Patterson JT et al (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5(10):749\u2013757. https:\/\/doi.org\/10.1038\/NCHEMBIO.209","journal-title":"Nat Chem Biol"},{"issue":"12","key":"5966_CR66","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/dom.12735","volume":"18","author":"SJ Henderson","year":"2016","unstructured":"Henderson SJ, Konkar A, Hornigold DC et al (2016) Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates. Diabetes Obes Metab 18(12):1176\u20131190. https:\/\/doi.org\/10.1111\/dom.12735","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"5966_CR67","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1530\/JOE-19-0007","volume":"241","author":"S Kalavalapalli","year":"2019","unstructured":"Kalavalapalli S, Bril F, Guingab J et al (2019) Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis. J Endocrinol 241(3):293\u2013305. https:\/\/doi.org\/10.1530\/JOE-19-0007","journal-title":"J Endocrinol"},{"issue":"4","key":"5966_CR68","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/J.JHEPR.2019.07.002","volume":"1","author":"A Gastaldelli","year":"2019","unstructured":"Gastaldelli A, Cusi K (2019) From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. JHEP Rep 1(4):312\u2013328. https:\/\/doi.org\/10.1016\/J.JHEPR.2019.07.002","journal-title":"JHEP Rep"},{"key":"5966_CR69","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/nejmoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, Cusi K et al (2021) A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med 384:1113\u20131124. https:\/\/doi.org\/10.1056\/nejmoa2028395","journal-title":"N Engl J Med"},{"issue":"10","key":"5966_CR70","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/APT.15503","volume":"50","author":"RK Pai","year":"2019","unstructured":"Pai RK, Kleiner DE, Hart J et al (2019) Standardizing the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials. Aliment Pharmacol Ther 50(10):1100. https:\/\/doi.org\/10.1111\/APT.15503","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"5966_CR71","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/J.JHEP.2022.01.011","volume":"76","author":"EM Brunt","year":"2022","unstructured":"Brunt EM, Clouston AD, Goodman Z et al (2022) Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD. J Hepatol 76(5):1030\u20131041. https:\/\/doi.org\/10.1016\/J.JHEP.2022.01.011","journal-title":"J Hepatol"},{"issue":"6","key":"5966_CR72","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/J.JHEP.2020.06.025","volume":"73","author":"BA Davison","year":"2020","unstructured":"Davison BA, Harrison SA, Cotter G et al (2020) Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials. J Hepatol 73(6):1322\u20131332. https:\/\/doi.org\/10.1016\/J.JHEP.2020.06.025","journal-title":"J Hepatol"},{"key":"5966_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/metabo11020073","volume":"11","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Petracca G, Beatrice G, Csermely A, Lonardo A, Targher G (2021) Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials. Metabolites 11:1\u201313","journal-title":"Metabolites"},{"issue":"6","key":"5966_CR74","doi-asserted-by":"publisher","first-page":"E1746","DOI":"10.1152\/ajpendo.00460.2007","volume":"293","author":"PL McClean","year":"2007","unstructured":"McClean PL, Irwin N, Cassidy RS, Holst JJ, Gault VA, Flatt PR (2007) GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet. Am J Physiol Endocrinol Metab 293(6):E1746\u2013E1755. https:\/\/doi.org\/10.1152\/ajpendo.00460.2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"4","key":"5966_CR75","doi-asserted-by":"publisher","first-page":"868","DOI":"10.2337\/DB16-0758","volume":"66","author":"E Joo","year":"2017","unstructured":"Joo E, Harada N, Yamane S et al (2017) Inhibition of gastric inhibitory polypeptide receptor signaling in adipose tissue reduces insulin resistance and hepatic steatosis in high-fat diet\u2013fed mice. Diabetes 66(4):868\u2013879. https:\/\/doi.org\/10.2337\/DB16-0758","journal-title":"Diabetes"},{"key":"5966_CR76","doi-asserted-by":"publisher","first-page":"170208","DOI":"10.1016\/J.PEPTIDES.2019.170208","volume":"125","author":"SK Thondam","year":"2020","unstructured":"Thondam SK, Cuthbertson DJ, Wilding JPH (2020) The influence of glucose-dependent insulinotropic polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Peptides 125:170208. https:\/\/doi.org\/10.1016\/J.PEPTIDES.2019.170208","journal-title":"Peptides"},{"issue":"6","key":"5966_CR77","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","volume":"10","author":"A Gastaldelli","year":"2022","unstructured":"Gastaldelli A, Cusi K, Fern\u00e1ndez Land\u00f3 L, Bray R, Brouwers B, Rodr\u00edguez \u00c1 (2022) Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 10(6):393\u2013406. https:\/\/doi.org\/10.1016\/S2213-8587(22)00070-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"5966_CR78","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1111\/dom.14035","volume":"22","author":"A Kannt","year":"2020","unstructured":"Kannt A, Madsen AN, Kammermeier C et al (2020) Incretin combination therapy for the treatment of non-alcoholic steatohepatitis. Diabetes Obes Metab 22(8):1328\u20131338. https:\/\/doi.org\/10.1111\/dom.14035","journal-title":"Diabetes Obes Metab"},{"issue":"35","key":"5966_CR79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/sciadv.aaz9890","volume":"6","author":"CA Gilroy","year":"2020","unstructured":"Gilroy CA, Capozzi ME, Varanko AK et al (2020) Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia. Sci Adv 6(35):1\u201313. https:\/\/doi.org\/10.1126\/sciadv.aaz9890","journal-title":"Sci Adv"},{"issue":"3","key":"5966_CR80","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/J.JHEP.2022.04.003","volume":"77","author":"N Alkhouri","year":"2022","unstructured":"Alkhouri N, Herring R, Kabler H et al (2022) Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. J Hepatol 77(3):607\u2013618. https:\/\/doi.org\/10.1016\/J.JHEP.2022.04.003","journal-title":"J Hepatol"},{"key":"5966_CR81","doi-asserted-by":"publisher","first-page":"101090","DOI":"10.1016\/j.molmet.2020.101090","volume":"46","author":"LL Baggio","year":"2020","unstructured":"Baggio LL, Drucker DJ (2020) Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease. Mol Metab 46:101090","journal-title":"Mol Metab"},{"issue":"5","key":"5966_CR82","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/S13300-022-01239-7","volume":"13","author":"T Miyake","year":"2022","unstructured":"Miyake T, Yoshida O, Matsuura B et al (2022) additional effect of luseogliflozin on semaglutide in nonalcoholic steatohepatitis complicated by type 2 diabetes mellitus: an open-label, randomized, parallel-group study. Diabetes Ther 13(5):1083\u20131096. https:\/\/doi.org\/10.1007\/S13300-022-01239-7","journal-title":"Diabetes Ther"},{"issue":"2","key":"5966_CR83","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2337\/DB20-0162","volume":"70","author":"P Zizzari","year":"2021","unstructured":"Zizzari P, He R, Falk S et al (2021) CB1 and GLP-1 receptors cross talk provides new therapies for obesity. Diabetes 70(2):415\u2013422. https:\/\/doi.org\/10.2337\/DB20-0162","journal-title":"Diabetes"},{"issue":"5","key":"5966_CR84","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/OBY.2006.84","volume":"14","author":"The Look AHEAD Research Group","year":"2006","unstructured":"The Look AHEAD Research Group (2006) The Look AHEAD study: a description of the lifestyle intervention and the evidence supporting it. Obesity 14(5):737\u2013752. https:\/\/doi.org\/10.1038\/OBY.2006.84","journal-title":"Obesity"},{"issue":"3","key":"5966_CR85","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/S13679-019-00345-1","volume":"8","author":"KT Brunner","year":"2019","unstructured":"Brunner KT, Henneberg CJ, Wilechansky RM, Long MT (2019) Nonalcoholic fatty liver disease and obesity treatment. Curr Obes Rep 8(3):220\u2013228. https:\/\/doi.org\/10.1007\/S13679-019-00345-1","journal-title":"Curr Obes Rep"},{"issue":"10","key":"5966_CR86","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1016\/J.CGH.2021.01.023","volume":"20","author":"MH Malespin","year":"2022","unstructured":"Malespin MH, Barritt AS, Watkins SE et al (2022) Weight loss and weight regain in usual clinical practice: results from the TARGET-NASH observational cohort. Clin Gastroenterol Hepatol 20(10):2393-2395.e4. https:\/\/doi.org\/10.1016\/J.CGH.2021.01.023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5966_CR87","doi-asserted-by":"publisher","first-page":"106174","DOI":"10.1016\/J.CCT.2020.106174","volume":"97","author":"SA Harrison","year":"2020","unstructured":"Harrison SA, Calanna S, Cusi K et al (2020) Semaglutide for the treatment of non-alcoholic steatohepatitis: trial design and comparison of non-invasive biomarkers. Contemp Clin Trials 97:106174. https:\/\/doi.org\/10.1016\/J.CCT.2020.106174","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"5966_CR88","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/OBY.23621","volume":"31","author":"I Lingvay","year":"2023","unstructured":"Lingvay I, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics. Obesity 31(1):111\u2013122. https:\/\/doi.org\/10.1002\/OBY.23621","journal-title":"Obesity"},{"issue":"10","key":"5966_CR89","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL et al (2021) Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 9(10):653\u2013662. https:\/\/doi.org\/10.1016\/S2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10019","key":"5966_CR90","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","volume":"387","author":"MJ Armstrong","year":"2016","unstructured":"Armstrong MJ, Gaunt P, Aithal GP et al (2016) Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387(10019):679\u2013690. https:\/\/doi.org\/10.1016\/S0140-6736(15)00803-X","journal-title":"Lancet"},{"issue":"9","key":"5966_CR91","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/DOM.12680","volume":"18","author":"A Dutour","year":"2016","unstructured":"Dutour A, Abdesselam I, Ancel P et al (2016) Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy. Diabetes Obes Metab 18(9):882\u2013891. https:\/\/doi.org\/10.1111\/DOM.12680","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"5966_CR92","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1002\/HEP.30320","volume":"69","author":"J Yan","year":"2019","unstructured":"Yan J, Yao B, Kuang H et al (2019) Liraglutide, sitagliptin, and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. Hepatology 69(6):2414\u20132426. https:\/\/doi.org\/10.1002\/HEP.30320","journal-title":"Hepatology"},{"issue":"5","key":"5966_CR93","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/LIV.14065","volume":"39","author":"J Khoo","year":"2019","unstructured":"Khoo J, Hsiang JC, Taneja R et al (2019) Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non-alcoholic fatty liver disease. Liver Int 39(5):941\u2013949. https:\/\/doi.org\/10.1111\/LIV.14065","journal-title":"Liver Int"},{"issue":"5","key":"5966_CR94","doi-asserted-by":"publisher","first-page":"e3292","DOI":"10.1002\/DMRR.3292","volume":"36","author":"L Liu","year":"2020","unstructured":"Liu L, Yan H, Xia MF et al (2020) Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes. Diabetes Metab Res Rev 36(5):e3292. https:\/\/doi.org\/10.1002\/DMRR.3292","journal-title":"Diabetes Metab Res Rev"},{"issue":"1","key":"5966_CR95","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/S00125-019-05021-6","volume":"63","author":"MB Bizino","year":"2020","unstructured":"Bizino MB, Jazet IM, de Heer P et al (2020) Placebo-controlled randomised trial with liraglutide on magnetic resonance endpoints in individuals with type 2 diabetes: a pre-specified secondary study on ectopic fat accumulation. Diabetologia 63(1):65\u201374. https:\/\/doi.org\/10.1007\/S00125-019-05021-6","journal-title":"Diabetologia"},{"issue":"11","key":"5966_CR96","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1007\/S00125-020-05265-7","volume":"63","author":"MS Kuchay","year":"2020","unstructured":"Kuchay MS, Krishan S, Mishra SK et al (2020) Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia 63(11):2434\u20132445. https:\/\/doi.org\/10.1007\/S00125-020-05265-7","journal-title":"Diabetologia"},{"key":"5966_CR97","doi-asserted-by":"publisher","first-page":"108487","DOI":"10.1016\/j.diabres.2020.108487","volume":"170","author":"W Guo","year":"2020","unstructured":"Guo W, Tian W, Lin L, Xu X (2020) Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: a randomized placebo-controlled trial. Diabetes Res Clin Pract 170:108487. https:\/\/doi.org\/10.1016\/j.diabres.2020.108487","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"5966_CR98","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/J.CLINRE.2020.01.007","volume":"44","author":"LY Zhang","year":"2020","unstructured":"Zhang LY, Qu XN, Sun ZY, Zhang Y (2020) Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease. Clin Res Hepatol Gastroenterol 44(5):674\u2013680. https:\/\/doi.org\/10.1016\/J.CLINRE.2020.01.007","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"6","key":"5966_CR99","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/S2468-1253(23)00068-7","volume":"8","author":"R Loomba","year":"2023","unstructured":"Loomba R, Abdelmalek MF, Armstrong MJ et al (2023) Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol 8(6):511\u2013522. https:\/\/doi.org\/10.1016\/S2468-1253(23)00068-7","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"5966_CR100","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/HEP.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M et al (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41(6):1313\u20131321. https:\/\/doi.org\/10.1002\/HEP.20701","journal-title":"Hepatology"},{"issue":"1","key":"5966_CR101","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/MCG.0B013E3181DD1348","volume":"45","author":"R Juluri","year":"2011","unstructured":"Juluri R, Vuppalanchi R, Olson J et al (2011) Generalizability of the NASH CRN histological scoring system for nonalcoholic fatty liver disease. J Clin Gastroenterol 45(1):55\u201358. https:\/\/doi.org\/10.1097\/MCG.0B013E3181DD1348","journal-title":"J Clin Gastroenterol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-05966-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-023-05966-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-05966-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T19:06:53Z","timestamp":1722020813000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-023-05966-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":101,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5966"],"URL":"https:\/\/doi.org\/10.1007\/s00125-023-05966-9","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"13 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"TV has served on scientific advisory panels, been part of speaker bureaus, and served as a consultant to and\/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gilead, GSK, Mundipharma, Novo Nordisk, Sanofi and Sun Pharmaceuticals. CRA and AA declare that there are no relationships or activities that might bias, or be perceived to bias, their work.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"All authors were responsible for drafting the article and revising it critically for important intellectual content. All authors approved the version to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}